Bioquell Discussion Board http://www.iii.co.uk/investment/detail?code=cotn:BQE.L&display=discussion http://www.iii.co.uk/icons/logos/uk_logo.gif http://www.iii.co.uk tag:iii.co.uk,2003:tst.9661650 ')" target="_blank" rel="nofollow">http://www.ft.com/cms/s/0/9bd236a0-9dd5-11e1-9a9e-00144feabdc0.html#axzz1vKmV1sqD

18 May By biguglybear ]]> http://www.iii.co.uk/investment/detail?code=cotn:BQE.L&display=discussion&id=9661650&action=detail Sat, 19 May 2012 16:41:00 GMT biguglybear tag:iii.co.uk,2003:tst.9298110
If the price breaks above 125p then the chart indicates a move up to around 160p.

By biguglybear ]]> http://www.iii.co.uk/investment/detail?code=cotn:BQE.L&display=discussion&id=9298110&action=detail Wed, 15 Feb 2012 18:02:00 GMT biguglybear tag:iii.co.uk,2003:tst.8707665 02/09/2011 Miles Nolan
http://www.growthcompany.co.uk/recommendations/1651388/bioquell.thtml


Against low comparatives, bio-decontamination specialist Bioqeull (BQE) has quadrupled its pre-tax profits to £2m in the first half of 2011.

Based around hydrogen peroxide vapour Bioquell has developed a patent-protected system which eradicates bacteria and viruses at room temperature. The system is used by biotechnology institutions as well as hospitals as they fight to eliminate potentially life threatening 'superbugs'.

In the six months to June sales increased 11% to £20m, with the bio-decontamination arm hoisting its revenues 13% to £13.4m. Bioquell enjoyed higher demand for its kit in the UK and overseas, indeed it recently secured a $1m contract from China to use its products in research laboratories.

As bio-pharmaceutical companies continue to seek sterile facilities Bioquell should be well placed to win new business, particularly in light of pressure to stop using the human carcinogen formaldehyde to sterilise facilities. Growth in the US healthcare market has proved sluggish, however interest from developing countries is on the up.

Bioquell also owns TRaC, a testing and regulatory services firm that enjoyed a 8% hike in sales to £6.6m. It recently launched a new division branded as Early Stage Qualification (ESQ), this is to provide clients with advice on how best to design their products to comply with regulation.

House broker Investec predicts full-year pre-tax profits of £5.2m and EPS of 8.1p. Chief executive Nick Adams quips that Bioquell plans 'global domination' - an ambitious aim but its technology is certainly gaining traction. With net cash of £4.6m, and peers to TRaC selling for up to twice annual revenues Bioquell has an attractive niche and looks undervalued. Long-term buy.

Tags: Decontamination, Growth company, Main market, Nick Adams, Overseas expansion

Sector: Health Care Equipment & Services

Companies: Bioquell

Market cap: £43.8mPE Forecast: 12.9
Share price: 106p By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:BQE.L&display=discussion&id=8707665&action=detail Fri, 02 Sep 2011 13:04:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.8593134 Created: 29 July 2011 Written by: Algy Hall
http://www.investorschronicle.co.uk/StockScreen/article/20110729/3b8f662e-b865-11e0-ab56-00144f2af8e8/10-contrarian-stock-picks.jsp


Being a contrarian investor means going against the crowd and seeing value where others can't. When it comes to stock screening, one way of emulating this contrarian process is by focusing on fundamentals that the wider market may be ignoring. This is a strategy espoused by investment legend Ken Fisher in his best selling book Super Stocks, published in 1984. We've borrowed liberally from his stock picking method to create our contrarian screen.
The key aspect of Fisher's approach, set out in Super Stocks, was to focus on the price-to-sales ratio (PSR) to identify value, rather than the far more commonly used price-to-earnings ratio (PER). The reason behind this is that it is sales that ultimately drive a business's success. By contrast, earnings, Fisher argued, often fluctuate over the course of a company's development. That means if a good company's earnings become temporarily depressed, a PE-fixated market is likely to undervalue the company until the situation rights itself, presenting smart contrarian investors with an opportunity to buy in on the cheap.
Of course, there could be a good reason why the shares are valued on a small multiple of sales. For example, sales could be falling, the balance sheet could be shot, or the business may be incapable of generating profits from its turnover. Our screen therefore looks for a number of supplementary criteria beyond the PSR to identify companies that the market may be genuinely undervaluing rather than those that are cheap for good reason. Even with the quality checks, the companies that have made it through our tests look a risky bunch. But if their charms were obvious, you could hardly describe them as contrarian.
In fact, the criteria we've used for the screen are a bit different from Fisher's formulation in Super Stocks, but there is a big nod in that direction.
READ MORE...
We list the full criteria in part two and out of the 20 shares we've identified, we pick out our 10 favourites.
Part two of this feature will be available in today's issue of the Investors Chronicle magazine (cover date: 29 Jul- 4 Aug), or you can read it now

10 Bioquell (BQE)
Bio-decontamination specialist Bioquell has recently been hit by spending cuts in the life sciences sector and delayed military orders. However, while the company may be down, it is by no means out. Indeed, after a tough first half, Bioquell has been showing encouraging signs of recovery. Prospects look good for life sciences in the US and the company is making progress in gaining the permissions it needs to enter the Chinese market. As well as its decontamination business, its specialist testing and compliancy business TRaC is performing well. The company also has a decent cash pile, standing at nearly £5m at the year-end. So while the group still faces challenges, there is plenty of recovery potential there, too. By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:BQE.L&display=discussion&id=8593134&action=detail Fri, 29 Jul 2011 08:53:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.8454149 27/06/2011 Miles Nolan
http://www.growthcompany.co.uk/news/1633108/bioquell-expands-in-china.thtml


Having recently received the necessary approvals for its China based operation, bio-decontamination specialist Bioquell (BQE) has secured a useful $1 million contract.

Bioquell has delivered products to China via its Andover manufacturing base for five years using distributors, however it is now starting to see the benefits of a direct sales approach. The new contract is to supply specialist hydrogen peroxide vapour equipment, to research organisations which are within the Chinese Government's Ministry of Agriculture.

With a base in Shenzen the expectation is that the products will be delivered in the second half of 2011. In an interview with Growth Company Investor chief executive Nick Adams said 'there is plenty of opportunity in China to win new business'. Further out, he suggested new operations may be considered in Beijing and Shanghai, which would help augment growth in the healthcare and lifesciences markets.

After a tough 2010, last month Bioquell confirmed sales in the four months to April were ahead of the same period, with service revenues showing particular strength. It is witnessing opportunities in research and clinical trials, moreover demand in the US has picked up. Broker Investec predicts 2011 pre-tax profits of £5.7 million and EPS of 8.9p. At 113p, the shares are undervalued given its solid balance sheet and exposure to a growing niche market.

Tags: Bio-decontamination, China, Maintel, Nick Adams

Sector: Health Care Equipment & Services

Companies: Bioquell By SpikeyDT ]]> http://www.iii.co.uk/investment/detail?code=cotn:BQE.L&display=discussion&id=8454149&action=detail Mon, 27 Jun 2011 12:09:00 GMT SpikeyDT tag:iii.co.uk,2003:tst.7972233
L.O By Limit Order ]]> http://www.iii.co.uk/investment/detail?code=cotn:BQE.L&display=discussion&id=7972233&action=detail Wed, 16 Mar 2011 06:19:00 GMT Limit Order tag:iii.co.uk,2003:tst.7969300 http://www.iii.co.uk/investment/detail?code=cotn:BQE.L&display=discussion&id=7969300&action=detail Tue, 15 Mar 2011 14:34:00 GMT bbluesky tag:iii.co.uk,2003:tst.7445487 Cheers,
BD By Business Decathlete ]]> http://www.iii.co.uk/investment/detail?code=cotn:BQE.L&display=discussion&id=7445487&action=detail Tue, 14 Dec 2010 16:39:00 GMT Business Decathlete tag:iii.co.uk,2003:tst.7428189 http://www.iii.co.uk/investment/detail?code=cotn:BQE.L&display=discussion&id=7428189&action=detail Fri, 10 Dec 2010 19:40:00 GMT bbluesky tag:iii.co.uk,2003:tst.7379723 http://www.iii.co.uk/investment/detail?code=cotn:BQE.L&display=discussion&id=7379723&action=detail Fri, 03 Dec 2010 13:35:00 GMT BuskerBoy tag:iii.co.uk,2003:tst.7334886 http://www.iii.co.uk/investment/detail?code=cotn:BQE.L&display=discussion&id=7334886&action=detail Fri, 26 Nov 2010 16:38:00 GMT totalfluke tag:iii.co.uk,2003:tst.7333694 bid 115

why the huge spread? By Ray555 ]]> http://www.iii.co.uk/investment/detail?code=cotn:BQE.L&display=discussion&id=7333694&action=detail Fri, 26 Nov 2010 14:11:00 GMT Ray555 tag:iii.co.uk,2003:tst.7319132 http://www.iii.co.uk/investment/detail?code=cotn:BQE.L&display=discussion&id=7319132&action=detail Wed, 24 Nov 2010 13:57:00 GMT Business Decathlete tag:iii.co.uk,2003:tst.7316918
"The one analyst offering a 12 month price target expects the share price price of Bioquell PLC (BQE:LSE) to remain relatively unchanged over the next year."

Which was the opinion given within the last 4 weeks.

Anyone have an opinion? By Kris_Kuch ]]> http://www.iii.co.uk/investment/detail?code=cotn:BQE.L&display=discussion&id=7316918&action=detail Wed, 24 Nov 2010 09:55:00 GMT Kris_Kuch tag:iii.co.uk,2003:tst.7291365 Happy to hear other opinions and it was nice to spot this before NT for once!
Regards, BD By Business Decathlete ]]> http://www.iii.co.uk/investment/detail?code=cotn:BQE.L&display=discussion&id=7291365&action=detail Fri, 19 Nov 2010 10:05:00 GMT Business Decathlete